> ## Content Index
> Fetch the complete content index at: https://www.huntingalphas.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Did Pfizer Overpay For Yet Another Acquisition? (Archive)
- URL: https://www.huntingalphas.com/did-pfizer-overpay-for-yet-another-acquisition-archive/
- Published: 2025-10-18T13:20:00.000Z
- Updated: 2026-02-28T19:05:08.000Z
- Description: Pfizer’s Metsera obesity deal looks reasonably priced, but fundamentals still justify only a hold.
- Author: Vish (Hunting Alphas)
- Tags: 5-Minute Pitches, #noindex, Archive, #sa-origin, PFE, Healthcare

*This 5-Minute Pitch was originally published on Seeking Alpha before the launch of the Hunting Alphas website. It is shared here to showcase my previous work and track record. New 5-Minute Pitches published on this site will not be disseminated anywhere else.*

## Elevator Pitch

- After Pfizer failed to crack the obesity management drug market organically, I feared that it might resort to an overpriced M&A.
- As expected, PFE is entering the obesity drug market via an acquisition. But I am pleasantly surprised to see that the valuation it paid for this M&A is rather reasonable.
- To avoid tariff hits, Pfizer is trying to stay on the good side of the United States. But this is coming at the cost of FCF and margin hits.
- PFE stock looks undervalued vs. pharmaceutical peers. But a weak earnings growth outlook may justify its relatively discounted valuations.
- Technical analysis shows seller momentum slowing, but no convincing buyer activity yet to signal a trend reversal.

Read the full article [here](https://seekingalpha.com/article/4830970-did-pfizer-overpay-for-yet-another-acquisition?ref=huntingalphas.com).

#### Disclosures and Disclaimers

**Past performance ≠ future results. Not investment advice. See* [**full Disclaimer*](https://www.huntingalphas.com/disclaimer/)**.*